According to a recent LinkedIn post from Cagent Vascular Inc, clinicians at CHU Saint-Pierre have utilized the company’s Serration Remodeling Therapy (SRT) technology in Belgium and Luxembourg. The post highlights multidisciplinary collaboration at UMC Sint-Pieter – CHU Saint-Pierre and acknowledges support from interventionalist Lorenzo Patrone in advancing adoption of this therapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests that SRT is being positioned as an alternative to traditional vessel remodeling techniques, with an emphasis on more controlled and durable outcomes in peripheral vascular care. For investors, expanding clinical use in new European markets could support longer-term revenue potential, strengthen clinical evidence, and enhance Cagent Vascular’s competitive positioning in limb-salvage and endovascular treatment segments.
The emphasis on partnership with leading hospitals may indicate a strategy focused on key reference centers to drive broader regional uptake. If these collaborations translate into routine clinical use and favorable outcomes data, Cagent Vascular could improve its prospects for reimbursement, market penetration, and eventual scaling of its therapy platform across additional geographies.